480 related articles for article (PubMed ID: 32841351)
21. Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials.
Xu B; Kang B; Zhou J
Clin Res Cardiol; 2024 Jun; 113(6):910-923. PubMed ID: 38353684
[TBL] [Abstract][Full Text] [Related]
22. The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis.
Bai Y; Jin J; Zhou W; Zhang S; Xu J
Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1365-1374. PubMed ID: 33812735
[TBL] [Abstract][Full Text] [Related]
23. Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Tang H; Yang K; Li X; Song Y; Han J
Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):161-172. PubMed ID: 32017292
[TBL] [Abstract][Full Text] [Related]
24. Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Li D; Wu T; Wang T; Wei H; Wang A; Tang H; Song Y
Pharmacoepidemiol Drug Saf; 2020 May; 29(5):582-590. PubMed ID: 32124527
[TBL] [Abstract][Full Text] [Related]
25. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Lu J; Tang L; Meng H; Zhao J; Liang Y
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
[TBL] [Abstract][Full Text] [Related]
26. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
Wang H; Yang J; Chen X; Qiu F; Li J
Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
[TBL] [Abstract][Full Text] [Related]
27. Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials.
Cheng L; Li YY; Hu W; Bai F; Hao HR; Yu WN; Mao XM
Diabetes Metab; 2019 Oct; 45(5):436-445. PubMed ID: 30738154
[TBL] [Abstract][Full Text] [Related]
28. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
Seko Y; Sumida Y; Sasaki K; Itoh Y; Iijima H; Hashimoto T; Ishii S; Inagaki N
J Gastroenterol; 2018 Jan; 53(1):140-151. PubMed ID: 28669071
[TBL] [Abstract][Full Text] [Related]
29. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
[TBL] [Abstract][Full Text] [Related]
30. Effect of sodium-glucose cotransporter-2 inhibitors on myocardial infarction incidence: A systematic review and meta-analysis of randomized controlled trials and cohort studies.
Huang X; Dannya E; Liu X; Yu Y; Tian P; Li Z
Diabetes Obes Metab; 2024 Mar; 26(3):1040-1049. PubMed ID: 38086546
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis.
Jingfan Z; Ling L; Cong L; Ping L; Yu C
Arch Endocrinol Metab; 2019; 63(5):478-486. PubMed ID: 31271575
[TBL] [Abstract][Full Text] [Related]
32. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
33. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
[TBL] [Abstract][Full Text] [Related]
34. [Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor.
Merész G; Szabó S; Dóczy V; Hölgyesi Á; Szakács Z
Orv Hetil; 2020 Mar; 161(13):491-501. PubMed ID: 32202151
[TBL] [Abstract][Full Text] [Related]
35. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
Chen Z; Li G
Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
[TBL] [Abstract][Full Text] [Related]
36. Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Zou H; Liu L; Guo J; Wang H; Liu S; Xing Y; Deng C; Xiao Y; Zhou Z
J Diabetes Investig; 2021 Apr; 12(4):546-556. PubMed ID: 33245620
[TBL] [Abstract][Full Text] [Related]
37. Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis.
Wang A; Yang K; Wang T; Zhang N; Tang H; Feng X
Diabetes Metab Res Rev; 2020 Jan; 36(1):e3174. PubMed ID: 31050384
[TBL] [Abstract][Full Text] [Related]
38. Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.
Tang H; Fang Z; Wang T; Cui W; Zhai S; Song Y
Am J Cardiol; 2016 Dec; 118(11):1774-1780. PubMed ID: 27666177
[TBL] [Abstract][Full Text] [Related]
39. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
Lam CSP; Ramasundarahettige C; Branch KRH; Sattar N; Rosenstock J; Pratley R; Del Prato S; Lopes RD; Niemoeller E; Khurmi NS; Baek S; Gerstein HC
Circulation; 2022 Feb; 145(8):565-574. PubMed ID: 34775781
[TBL] [Abstract][Full Text] [Related]
40. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis.
Guo M; Ding J; Li J; Wang J; Zhang T; Liu C; Huang W; Long Y; Gao C; Xu Y
Diabetes Obes Metab; 2018 Aug; 20(8):1977-1982. PubMed ID: 29573118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
